Admissions now open at https://bit.ly/4wBV333 for UWA India's Mumbai and Chennai campuses, with scholarships available for eligible students.
MELBOURNE, Australia, July 15, 2026 /PRNewswire/ -- The University of Western Australia (UWA), a Global Top 100 university and founding member of Australia's prestigious Group of Eight (Go8), has appointed SRM Technologies as its Information Technology partner for the establishment of UWA's India International Branch Campuses in Mumbai and Chennai.
Kannan Natarajan, Global Head - Education & Public Sector Business, SRM Technologies, and Director, SRM Technologies Australia Pty Ltd. said: "Education technology is one of SRM Technologies' core strengths. Our ability to rapidly implement and manage complete digital ecosystems for international universities establishing campuses in India has become a key differentiator. We are proud to partner with The University of Western Australia in building a world-class digital campus experience."
David Das, Chief Operating Officer, UWA India, said on the appointment, "As we establish UWA's India International Branch Campuses, it was critical to partner with an organisation that understands both the higher education sector and the technology required to support a world-class student experience. SRM Technologies brings proven expertise in delivering integrated digital campus solutions, and this partnership will ensure our campuses in Mumbai and Chennai are equipped with secure, scalable and future-ready technology from day one."
The partnership will see SRM Technologies design, implement and manage the University's end-to-end digital campus ecosystem, enabling UWA India to deliver a seamless student, academic and administrative experience from day one. The entire technology environment is being deployed within an accelerated five-month implementation timeline, supporting UWA India's launch for the 2026-27 academic year.
The appointment further strengthens SRM Technologies' position as a leading digital transformation partner for international universities establishing operations in India through comprehensive, end-to-end technology solutions. Under the multi-year engagement, SRM Technologies' Education Technology Business Unit is implementing and managing UWA India's complete technology ecosystem, including Admissions, Student Information System, finance, human resources, campus networking, enterprise applications, IT infrastructure and managed support services. The integrated platform has been designed to provide a secure, scalable and future-ready digital foundation for UWA's India campuses.
Beyond implementation, SRM Technologies will provide ongoing application management, infrastructure operations and technology support, ensuring a reliable and connected digital experience for students, faculty and staff.
Manivannan S, CEO, SRM Technologies, said: "Education has been at the heart of SRM for over four decades. As universities worldwide respond to increasing student mobility, international branch campuses, and the growing adoption of hybrid learning, we see tremendous opportunities to help institutions modernize their digital ecosystems. Our strategic focus is on Australia and the United States, where we combine deep EdTech expertise with an outcome-based delivery approach to help education institutions accelerate their digital transformation and deliver exceptional experiences for students, faculty, and administrators."
SRM Technologies also serves on the Victorian Government's School Software Panel in Australia, delivering Unified School Management System solutions across K-12 education institutions.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
The University of Western Australia appoints SRM Technologies as Information Technology Partner for its India Branch Campuses
Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue
PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results reflect strong growth across its core businesses, improved operating efficiency, and accelerating demand for AI-enabled drug discovery services.
The AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period, driven by demand from AI-focused biotechnology companies and pharmaceutical innovators. Gene-to-Protein accounted for approximately 66% of GenScript Life Science Group revenue and remained the company's primary growth engine.
GenScript's Gene-to-Protein platform combines scientific expertise, automation, and global manufacturing capacity in an integrated workflow spanning discovery, experimental validation, early development, and production support. As AI increases the scale and complexity of drug discovery, these capabilities help customers validate candidates and advance programs with greater speed and reliability.
"Our first-half results reflect strong execution across the portfolio, with our core businesses driving both revenue growth and improved profitability," said Sherry Shao, Rotating CEO of GenScript. "We see significant long-term opportunity as AI reshapes life sciences and increases demand for experimental validation and development services. By expanding our global Gene-to-Protein platform, automation, digital manufacturing, and delivery network, we are strengthening GenScript's role as a critical infrastructure partner for AI-enabled drug discovery."
First-Half 2026 Highlights
GenScript Life Science Group
- Revenue of approximately US$319.0 million, up 28.8%
- Adjusted gross profit of approximately US$184.5 million, up 46.1%
- Adjusted operating profit of approximately US$94.0 million, up 102.8%
- Gene-to-Protein accounted for approximately 66% of segment revenue and remained the primary growth engine
AI-Enabled Drug Discovery
- AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period
- Growth reflects deeper engagement with AI drug discovery companies and increasing demand for protein engineering, biologics discovery, and development services, reinforcing GenScript's position as a validation and infrastructure partner within the AI drug discovery ecosystem
ProBio
- Revenue increased 34.2% on a comparable basis to approximately US$61.1 million
- New orders increased 54%
- Adjusted operating loss narrowed 22.5% to US$24.3 million
- Continued order growth and improving operating efficiency support ProBio's expectation of achieving positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2027
Bestzyme
- Revenue of approximately US$30.4 million, up 7.4%
- Adjusted gross profit of approximately US$13.0 million, up 14.0%
Integrated Capabilities Support Growth Across the Portfolio
The recovery in global biopharmaceutical research activity and the expanding use of AI are increasing the number and complexity of programs moving from computational design into experimental validation, development, and production. This shift is creating demand for integrated scientific, automation, and manufacturing infrastructure that can support customers across the drug-development workflow.
GenScript connects gene synthesis, protein production, antibody discovery, biologics development, automation, and global manufacturing in a single workflow. This infrastructure enables AI-focused biotechnology companies and pharmaceutical innovators to validate more candidates, identify viable programs, and advance them through early development and production without coordinating multiple service providers.
To support rising demand, GenScript continues to invest across its global discovery and manufacturing network, expanding capacity, shortening turnaround times, and enhancing automation and digital workflows. These investments are improving consistency and scalability as AI-driven customer projects grow increasingly complex.
Across the portfolio, ProBio benefited from growing demand for biologics development and manufacturing services while improving operating performance and building an order base that supports future revenue growth. Bestzyme continues to invest in enzyme engineering and AI-enabled synthetic biology technologies designed to improve research efficiency, reduce production costs, and accelerate new product development.
Outlook
GenScript enters the second half of 2026 with continued momentum across GenScript Life Science Group, ProBio, and Bestzyme, supported by a growing order base across its core businesses.
The company expects higher demand, increased utilization across its global network, and further operating leverage to support continued revenue growth and profitability improvement. Ongoing investment in technology, automation, and capacity is expanding GenScript's ability to support larger and more complex AI-enabled drug discovery programs, while ProBio's growing order base and Bestzyme's enzyme engineering and AI-enabled synthetic biology capabilities provide additional platforms for long-term growth. As adoption expands across these businesses, GenScript expects to deepen customer relationships, strengthen global delivery, and build its position as a critical infrastructure partner supporting next-generation therapeutic and biotechnology innovation.
Additional financial information, including consolidated and segment results, is available in GenScript's First-Half 2026 Results Announcement published on The Stock Exchange of Hong Kong Limited on August 16, 2026, as well as on the GenScript website.
About GenScript Biotech Corporation
Founded in New Jersey in 2002, GenScript Biotech Corporation supports biotechnology and healthcare innovation through its integrated portfolio of research, development, and manufacturing services. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has more than 6,100 employees and serves over 200,000 customers across more than 100 countries and regions, including the world's top 20 pharmaceutical companies. For more information, visit www.genscript.com.
Investor and Media Contacts
Investor Relations
Email: ir@genscript.com
Media Contact
Kate Grusich, Senior Corporate Communications Manager
Katherina.Grusich@genscript.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
